SHSE:600211 (China)
Â
Class A
Â¥
47.48
(-0.57%)
Apr 24
Business Description
Tibet Rhodiola Pharmaceutical Holding Co
NAICS : 325412
SIC : 2834
ISIN : CNE000000ZW7
Share Class Description:
SHSE:600211: Class ACompare
Compare
Traded in other countries / regions
600211.China IPO Date
1999-07-21Description
Tibet Rhodiola Pharmaceutical Holding Co is a Chinese company producing biological products and traditional Tibetan medicines.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.73 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 0.55 | |||||
| Interest Coverage | 106.01 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 8.09 | |||||
| Beneish M-Score | -2.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 31.6 | |||||
| 3-Year EBITDA Growth Rate | 21.1 | |||||
| 3-Year EPS without NRI Growth Rate | 29.1 | |||||
| 3-Year FCF Growth Rate | 71.3 | |||||
| 3-Year Book Growth Rate | 9.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.66 | |||||
| 9-Day RSI | 66.8 | |||||
| 14-Day RSI | 61.26 | |||||
| 6-1 Month Momentum % | -2.43 | |||||
| 12-1 Month Momentum % | -26.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.87 | |||||
| Quick Ratio | 2.78 | |||||
| Cash Ratio | 2.01 | |||||
| Days Inventory | 245.77 | |||||
| Days Sales Outstanding | 59.89 | |||||
| Days Payable | 101.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.52 | |||||
| Dividend Payout Ratio | 0.41 | |||||
| 3-Year Dividend Growth Rate | 37 | |||||
| Forward Dividend Yield % | 4.08 | |||||
| 5-Year Yield-on-Cost % | 10.73 | |||||
| Shareholder Yield % | 2.24 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.05 | |||||
| Operating Margin % | 39.21 | |||||
| Net Margin % | 25.55 | |||||
| FCF Margin % | 33.24 | |||||
| ROE % | 24.15 | |||||
| ROA % | 17.48 | |||||
| ROIC % | 57.56 | |||||
| ROC (Joel Greenblatt) % | 137.39 | |||||
| ROCE % | 26.91 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.7 | |||||
| PE Ratio without NRI | 9.96 | |||||
| Shiller PE Ratio | 36.81 | |||||
| Price-to-Owner-Earnings | 17.94 | |||||
| PEG Ratio | 0.66 | |||||
| PS Ratio | 3.75 | |||||
| PB Ratio | 3.52 | |||||
| Price-to-Tangible-Book | 3.76 | |||||
| Price-to-Free-Cash-Flow | 11.33 | |||||
| Price-to-Operating-Cash-Flow | 11.1 | |||||
| EV-to-EBIT | 10.95 | |||||
| EV-to-EBITDA | 10.95 | |||||
| EV-to-Revenue | 3.18 | |||||
| EV-to-FCF | 9.22 | |||||
| Price-to-Projected-FCF | 1.3 | |||||
| Price-to-Median-PS-Value | 0.73 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.62 | |||||
| Price-to-Graham-Number | 1.29 | |||||
| Price-to-Net-Current-Asset-Value | 5.45 | |||||
| Price-to-Net-Cash | 10.39 | |||||
| Earnings Yield (Greenblatt) % | 9.13 | |||||
| FCF Yield % | 8.85 | |||||
| Forward Rate of Return (Yacktman) % | 20.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tibet Rhodiola Pharmaceutical Holding Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,134.328 | ||
| EPS (TTM) (Â¥) | 3.23 | ||
| Beta | 1.38 | ||
| Volatility % | 32.59 | ||
| 14-Day RSI | 61.26 | ||
| 14-Day ATR (Â¥) | 1.344168 | ||
| 20-Day SMA (Â¥) | 45.3895 | ||
| 12-1 Month Momentum % | -26.83 | ||
| 52-Week Range (Â¥) | 35.04 - 64.47 | ||
| Shares Outstanding (Mil) | 247.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tibet Rhodiola Pharmaceutical Holding Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tibet Rhodiola Pharmaceutical Holding Co Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tibet Rhodiola Pharmaceutical Holding Co Frequently Asked Questions
What is Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211)'s stock price today?
The current price of SHSE:600211 is ¥47.48. The 52 week high of SHSE:600211 is ¥64.47 and 52 week low is ¥35.04.
When is next earnings date of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211)?
The next earnings date of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is .
Does Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) pay dividends? If so, how much?
The Dividend Yield %  of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is 2.52% (As of Today), Highest Dividend Payout Ratio of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) was 1.89. The lowest was 0.11. And the median was 0.4. The  Forward Dividend Yield % of Tibet Rhodiola Pharmaceutical Holding Co(SHSE:600211) is 4.08%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers